Not Blinded by B2B's Height

Gary gushes over his new eyesight. Let's see if his technical analysis vision on B2B stocks is 20/20.
Author:
Publish date:

In response to a recent column, many folks wanted more details on my

Lasik

eye surgery. Therefore, in addition to tackling

Matt.com's

B2B charts today, I'll give you a few words on what most people -- myself included -- describe as a minor miracle.

As background, I had worn glasses since I was 9 years old, and contacts on and off since 1976. And my eyes were off the charts as far as weakness. If 20/400 is about as bad as they can measure, I was far, far worse than that. About the best I could do on that "Big E" chart was see the light that illuminated the chart! Beyond that, I was hopeless.

So I found an eye surgeon who had an extensive background doing the Lasik procedure, and after a thorough exam, he assured me I was a candidate for the surgery. That was a week ago. And as you read this, my vision in one eye is 20/20 and the other 20/30. What happened in between?

This past Friday, at 8:30 a.m., the doctor re-examined my eyes, and then I went into the laser room. He put a few drops of local anesthetic into each eye, and after that, I didn't feel a thing. I was, however, wide awake, and that's nice, as the doctor talked me through the entire procedure.

The entire operation took about 15 to 20 minutes for both eyes. It wasn't painful at all, and at worst I'd describe the experience as disconcerting. At one point, the light in your eyes is a bit bright, and at another point, you go pretty much blind. But, really, it's all over so fast you hardly notice.

When he was done, I did not bolt from the table -- as some people have -- with perfect vision. No, it was more like some Vaseline had been put over my eyes. My recovery consisted of lying down with my eyes closed for about 20 minutes. They took a look at me after that, verified I was healing fine, I donned some sunglasses, and my wife Nancy drove me home. You do feel a little grittiness in your eyes, but if you've worn contacts for any stretch, the discomfort you feel is trivial.

Technician's Take: Join the discussion on

TSC message boards and

B2B.

After the procedure, they want you to nap for about three hours, and I did just that. And when you wake up? Miracle time.

Then

is when it hits you: You really can see better. And even better, my vision right now, while about as good as when I wore glasses, is improving every day. In fact, it will be quite a few months before it's as good as it gets. Neat stuff.

The cost for all this? It is not, as you might suspect, inexpensive. On the whole, I believe the price ranges from $2,000 to $3,000 per eye. And, as elective surgery, it's not generally covered by insurance.

But is it worth it? Hah! I would have paid double!

OK, hope that helps. Now, back to our regularly scheduled programming. On Monday, I tackled five of

JJC's

B2B picks. And technically, they were looking pretty spiffy. Can five of Matt.com's fare as well? Let's have a look.

It's funny -- before I looked at JJC's and Matt's B2B charts, I thought I'd find silly moonshot patterns. You know -- the ones that are begging to drop 100 points in a single day. Instead I found 10 pretty solid candidates that had excellent possibilities.

Therefore, based on the technicals alone, it's hard not to believe in some of these. That said, these plays are obviously very volatile, so make sure you think about your targets

and

your stops before you enter the trade. It's just when you think you can buy these stocks blindly and make money that you get your head handed to you.

Remember, eyes I can help you with. Your whole head is your responsibility.

Gary B. Smith is a freelance writer who trades for his own account from his Maryland home using technical analysis. At time of publication, he held no positions in any securities mentioned in this column, although holdings can change at any time. Under no circumstances does the information in this column represent a recommendation to buy or sell stocks. Smith writes five technical analysis columns for TheStreet.com each week, including Technician's Take, Charted Territory and TSC Technical Forum. While he cannot provide investment advice or recommendations, he welcomes your feedback at

gbsmith@attglobal.net.